scholarly journals Hepatitis D Seroprevalence in people with chronic hepatitis B in Lubumbashi (DRC)

2021 ◽  
Vol 14 (9) ◽  
pp. 3110-3116
Author(s):  
A.T. Kabamba ◽  
C.M. Mwamba ◽  
C.M. Nyembo ◽  
B.M. Kabamba ◽  
A.O. Longanga
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Blood Donors ◽  
Prise En Charge ◽  
Hepatitis D ◽  
Early Management ◽  
Hbsag Carriers ◽  
Tests De Diagnostic Rapide ◽  
First Time

Hepatitis B and D viruses are responsible for about 2 million deaths annually worldwide. In co-infection with hepatitis B (HBV) and D (VHD) viruses, the prognosis for hepatitis B is exacerbated by HDV. This study aimed at estimating the seroprevalence of hepatitis D among blood donors at Cliniques Universitaires and Hôpital Jason Sendwe in Lubumbashi. Screening for HBsAg was performed using rapid diagnostic tests and then confirmed by the Liaison XL test which was also used for screening for anti-HDV antibodies. Of 200 blood donors who tested positive for HBsAg, only four (2%) tested positive for anti-HDV antibodies. This study has the merit of highlighting, for the first time, HBV-HDV co-infection in Lubumbashi. Hepatitis D should be screened for in all HBsAg carriers with severe or chronic hepatitis in order to allow early management of these patients and thus avoid aggravation of liver disease. The limitations of this study are the lack of data on the course of liver disease, the genotype of HBV and HDV, the viral load of HDV and any current treatments. Les virus des hépatites B et D sont responsables d’environ 2 millions de décès annuellement dans le monde. Lors de la coïnfection par les virus de l’hépatite B (VHB) et D (VHD), le pronostic de l’hépatite B est aggravé par le VHD. Cette étude voudrait estimer la séroprévalence de l’hépatite D chez les donneurs de sang des Cliniques Universitaires et Hôpital Jason Sendwe de Lubumbashi. Le dépistage de l’AgHBs a été réalisé au moyen des tests de diagnostic rapide puis confirmé par test de Liaison XL qui a été également utilisé pour le dépistage d’anticorps anti-VHD. Sur 200 donneurs de sang testés positifs pour l’AgHBs, seuls quatre (2%) se sont révélés positifs en anticorps anti-VHD. Cette étude a le mérite d’avoir mis en évidence, pour la première fois, la co-infection VHB-VHD à Lubumbashi. L’hépatite D devrait être recherchée chez tous porteurs d’AgHBs présentant une hépatite sévère ou chronique afin de permettre une prise en charge précoce de ces patients et éviter ainsi l’aggravation de la maladie hépatique. Le manque des données sur l’évolution de la maladie hépatique, le génotype de VHB et VHD, la charge virale de VHD et les traitements éventuels en cours constituent les limites de cette étude.

scholarly journals Hepatitis G virus infection in chronic liver disease

Gut ◽  
1998 ◽  
Vol 42 (1) ◽  
pp. 107-111 ◽  
Author(s):  
M Guilera ◽  
J C Sáiz ◽  
F X López-Labrador ◽  
E Olmedo ◽  
S Ampurdanés ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Blood Donors ◽  
Chronic Liver ◽  
Hepatitis G Virus ◽  
Cryptogenic Chronic Liver Disease

Background—The hepatitis G virus (HGV), a recently identified member of the Flaviviridae family, can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood.Aims—To evaluate the prevalence and meaning of HGV infection in a large series of patients with chronic liver disease.Subjects—Two hundred volunteer blood donors, 179 patients with chronic hepatitis C, 111 with chronic hepatitis B, 104 with alcoholic liver disease, 136 with hepatocellular carcinoma, and 24 with cryptogenic chronic liver disease were studied.Methods—HGV RNA was investigated in serum samples by reverse transcription and polymerase chain reaction amplification of the 5′ non-coding region of HCV and hybridisation to a specific probe. The main features of HGV RNA seropositive and seronegative patients were compared.Results—The prevalence of HGV infection was 3% in blood donors, 7% in chronic hepatitis C, 8% in chronic hepatitis B, 2% in alcoholic liver disease, 4% in hepatocellular carcinoma, and 8% in cryptogenic chronic liver disease. HGV infected patients tended to be younger than non-infected patients but no differences concerning sex, possible source of infection, clinical manifestations, biochemical and virological parameters, or severity of liver lesions were found.Conclusions—The prevalence of HGV infection in chronic liver disease seems to be relatively low in our area. Infection with HGV does not seem to play a significant pathogenic role in patients with chronic liver disease related to chronic HBV or HCV infection or to increased alcohol consumption, or in those with cryptogenic chronic liver disease.

scholarly journals Use of the LI-RADS classification in patients with cirrhosis due to infection with hepatitis B, C, or D, or infected with hepatitis B and D

2020 ◽  
Vol 53 (1) ◽  
pp. 14-20
Author(s):  
Rita de Cassia Ribeiro Pereira ◽  
Carolina Augusta Modena Heming ◽  
Thiago Ramos Tejo ◽  
Thais Cristina Lima de Oliveira ◽  
Rita do Socorro Uchoa da Silva ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Liver Lesions ◽  
Dynamic Computed Tomography ◽  
Hepatitis D ◽  
Contrast Enhanced ◽  
Level Of Agreement

Abstract Objective: To evaluate liver lesions, in accordance with the LI-RADS classification, using contrast-enhanced multiphase dynamic computed tomography in patients with hepatitis B, coinfected or not with hepatitis D, or with chronic hepatitis C, as well as to determine the level of agreement between radiologists. Materials and Methods: We evaluated 38 patients with hepatitis B, coinfected or not with hepatitis D, or with chronic hepatitis C, all of whom underwent contrast-enhanced multiphase dynamic computed tomography. For each examination, two radiologists selected up to three hepatic lesions, categorizing them in accordance with the LI-RADS classification and evaluating signs of chronic liver disease and portal hypertension. To determine the level of agreement between radiologists, we calculated the kappa statistic (κ) . Results: Radiologist 1 and radiologist 2 selected 56 and 48 liver lesions, respectively. According to radiologist 1 and radiologist 2, respectively, 27 (71%) and 23 (61%) of the 38 patients had at least one liver lesion; 13 (34%) and 12 (32%) had a LI-RADS 5 lesion (κ = 0.821); 19 (50%) and 16 (42%) had a hypervascular lesion (κ = 0.668); and 30 (79%) and 24 (63%) had splenomegaly (κ = 0.503). Both radiologists identified chronic liver disease in 31 (82%) of the patients (κ = 1.00). Conclusion: Lesions categorized as LI-RADS 5 were detected in approximately 32% of the patients, with almost perfect agreement between the radiologists. The level of agreement was substantial or moderate for the other LI-RADS categories.

scholarly journals Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up

1996 ◽  
Vol 10 (1) ◽  
pp. 21-25 ◽  
Author(s):  
Jean-Pierre Villeneuve ◽  
Bernard Willems
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Hbv Dna ◽  
Human Interferon ◽  
Hepatitis D ◽  
Serum Aminotransferases

The aim of treatment of chronic hepatitis B with interferon is to induce a transition from the replicative phase of the disease to a nonreplicative state, with loss of hepatitis B virus (HBV)-DNA, seroconversion from hepatitis B e antigen (HBeAg)-positive to anti-HBe antibody-positive, and normalization of liver enzymes. The authors’ experience in 22 patients with chronic hepatitis B treated with recombinant human interferon alpha-2b (5 MU/m2 subcutaneously three times/week for 16 weeks) is reported. Before treatment all patients had been positive for hepatitis B surface antigen (HBsAg) and HBeAg for at least six months, had abnormal serum aminotransferases, had no evidence of hepatitis D or human immunodeficiency virus (HIV) infection and had compensated liver disease. Eleven of 22 patients (50%) responded to treatment with loss of HBeAg and appearance of anti-HBe antibodies, and normalization of serum aminotransferases within six months of interferon cessation. Patients were followed for 3.4±1.2 years after treatment. Ten of 11 responders remained negative for HBeAg and HBV-DNA; one patient relapsed and responded to a second course of interferon with loss of HBeAg and HBV-DNA. Seven of the 11 nonresponders underwent spontaneous (n=5) or retreatment-induced (n=2) seroconversion from HBeAg to anti-HBe and loss of HBV-DNA during follow-up. The other four nonresponders remained positive for HBeAg and HBV-DNA; three of the four progressed to decompensated liver disease. It is concluded that interferon is an effective treatment of chronic hepatitis B in 50% of patients with features similar to those used as selection criteria in the present study. These criteria probably also identify patients who have a high likelihood of spontaneous HBeAg to anti-HBe seroconversion, and it is possible that the benefit of interferon is its acceleration of this seroconversion.

SEROPREVALENCE OF HIV AND HBsAg AMONGST BLOOD DONORS IN A TERTIARY CARE HOSPITAL, CHHATTISGARH.

2019 ◽  
Vol 3 (8) ◽  
Author(s):  
Anusha P ◽  
Bankar Nandkishor J ◽  
Karan Jain ◽  
Ramdas Brahmane ◽  
Dhrubha Hari Chandi
Keyword(s):  
Hepatitis B ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Tertiary Care ◽  
Laboratory Diagnosis ◽  
Blood Bank ◽  
Care Hospital ◽  
Medical College ◽  
The World ◽  
First Time

INTRODUCTION: India being the second highly populated nation in the world. HIV/AIDS has acquired pandemic proportion in the world. Estimate by WHO for current infection rate in Asia. India has the third largest HIV epidemic in the world. HIV prevalence in the age group 15-49 yrs was an estimate of 0.2%. India has been classified as an intermediate in the Hepatitis B Virus (HBV) endemic (HBsAg carriage 2-7%) zone with the second largest global pool of chronic HBV infections. Safety assessment of the blood supply, the quality of screening measures and the risk of transfusion transmitted infectious diseases (TTIs) in any country can be estimated by scrutinizing the files of blood donors. After the introduction of the blood banks and improved storage facilities, it became more extensively used. Blood is one of the major sources of TTIs like hepatitis B, hepatitis C, HIV, syphilis, and many other blood borne diseases. Disclosure of these threats brought a dramatic change in attitude of physicians and patients about blood transfusion. The objective of this study is to determine the seroprevalence of transfusion transmitted infections amidst voluntary blood donors at a rural tertiary healthcare teaching hospital in Chhattisgarh. MATERIAL AND METHODS: This retrospective study was carried out in Chandulal Chandrakar Memorial Medical College, Kachandur, Durg. Blood donors were volunteers, or and commercial donors who donated the blood and paid by patients, their families, or friends to replace blood used or expected to be used for patients from the blood bank of the hospital. After proper donation of blood routine screening of blood was carried out according to standard protocol. Laboratory diagnosis of HIV 1 and HIV 2 was carried out by ELISA test. Hepatitis B surface antigen was screened by using ELISA. RESULTS: A total of 1915 consecutive blood donors’ sera were screened at Chandulal Chandrakar Memorial Medical College, blood bank during study period. Of these 1914 were male and 1 female. The mean age of patients was found to be 29.34 years with standard deviation (SD) of 11.65 Years. Among all blood donors in present study, 759(39.63%) were first time donors and 1156(60.37%) were repeated donors. 1 patient was HIV positive in first donation group while 3 (75%) were positive in repeat donation group. 7 (38.9%) were HBsAg positive in in first donation group while 11(61.1%) were positive in repeat donation group. Two patients in first donation group had dual infection of HIV and HBsAg. CONCLUSION: Seropositivity was high in repeated donors as compared to first time donors. The incidence of HIV is observed to be 0.2% and that of HBsAg is 0.94%. Strict selection of blood donors should be done to avoid transfusion-transmissible infections during the window period.

Sign in / Sign up

Export Citation Format

Share Document